News Headlines Article

FDA weighs target population for Amgen cholesterol drug
Modern Healthcare

Federal health regulators said Monday a highly anticipated, experimental drug from Amgen significantly lowers bad cholesterol. But officials have questions about who should take the drug and whether to approve it based on currently available data.The Food and Drug Administration posted its review of Amgen’s Repatha ahead of a public meeting to consider its approval. Repatha is the part of a new class of injectable, cholesterol-lowing drugs that work differently than older, statin drugs.